鍾南山: COVID-19のトレーサビリティはまだ完了していません

On November 16th, 2020 Guanzhou International Bio-Forum was held in Guangzhou International Bio-Island, をテーマに “Scientific and Technological Innovation Leads a Healthy Future”. 鍾南山, winner of the Medal of the Republic and academician of Chinese Academy of Engineering, attended the forum and delivered a speech.Zhong Nanshan: COVID-19のトレーサビリティはまだ完了していません.

Zhong Nanshan said that it is unimaginable for so many people to meet together today in foreign countries. 現在のところ, there are still many major problems unsolved in COVID-19, the law of COVID-19 outbreak has not been understood, the traceability has not been completed, and there are no highly targeted and effective drugs. Pfizer vaccine abroad can prevent 90% of infections, and vaccine research and development in China is at a similar level.

Zhong Nanshan said that at present, there is a great contrast between China and foreign countries in the prevention and control of the epidemic situation, which is because China took the idea of “life first” as a guide and timely controlled the domestic epidemic situation at the early stage of the outbreak.

“This is very different from my experience in fighting SARS in 2003. At that time, scientific research was not done enough, but when the COVID-19 outbreak broke out, we had the support of science and technology. We could prevent and study while developing kits earlier and promote them quickly. ” Zhong Nanshan said that due to the combination of medical treatment and scientific research, the COVID-19 epidemic in China was quickly controlled.

Zhong Nanshan said that until today, many major problems of the epidemic have not been solved, such as the source of COVID-19 is still unclear, and targeted drugs have not yet appeared. Zhong Nanshan said that it depends on the combination of basic and clinical, clinical and enterprise. “Shorten this road a little, this is the direction of our efforts.”

According to Zhong Nanshan, Pfizer vaccine abroad can prevent 90% of infections. 実際には, the level of vaccine research and development in Guangdong and even China is similar, but the results of the first phase of the trial can only be announced.

On September 24th, at the 13th China Bio-industry Conference, Academician Zhong Nanshan said that the pneumonia epidemic in COVID-19 may continue to exist or develop this winter and next spring. He introduced that it takes 1 に 2 years to complete mass vaccination.